Published in Br Heart J on December 01, 1993
Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol (1999) 1.63
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax (1999) 1.07
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol (2009) 0.99
Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol (1996) 0.97
Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther (2015) 0.94
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest (2013) 0.93
The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol (2011) 0.88
Primary pulmonary hypertension: the pressure rises for a gene. J Clin Pathol (2000) 0.85
Dietary pulmonary hypertension. Thorax (1994) 0.84
A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone). ScientificWorldJournal (2015) 0.84
Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction. J Pharmacol Toxicol Methods (2011) 0.83
Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J (1995) 0.81
Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study. Lipids Health Dis (2012) 0.80
Chinese medicines for slimming still cause health problems. BMJ (2002) 0.78
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis (2015) 0.78
Genomics of pulmonary arterial hypertension: implications for therapy. Heart Fail Clin (2010) 0.76
Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review. MedGenMed (2006) 0.76
Appetite suppressants and pulmonary hypertension. Thorax (1997) 0.76
International Primary Pulmonary Hypertension Study. Br Heart J (1994) 0.75
Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells. Pulm Circ (2011) 0.75
Exploration of the pulmonary circulation. Festschrift to Professor Donald Heath. Thorax (1994) 0.75
Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction. Nutr J (2016) 0.75
Valvular heart disease with the use of fenfluramine-phentermine. Tex Heart Inst J (2011) 0.75
Pulmonary hypertension's variegated landscape: a snapshot. Pulm Circ (2017) 0.75
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
Clinically important respiratory effects of dust exposure and smoking in British coal miners. Am Rev Respir Dis (1988) 2.32
Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) (1981) 2.06
[Are the primary vascular forms of chronic pulmonary heart disease becoming more common?]. Schweiz Med Wochenschr (1968) 1.95
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
[A case of chronic pulmonary hypertension after fenfluramine intake]. Wien Klin Wochenschr (1982) 1.72
Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J (Clin Res Ed) (1986) 1.44
Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A (1986) 1.33
Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs (1975) 1.21
Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med (1990) 1.20
Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest (1992) 1.04
Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bull Eur Physiopathol Respir (1980) 0.95
Pulmonary hypertension and dexfenfluramine. Lancet (1992) 0.93
A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmacol Res (1990) 0.92
Pulmonary hypertension and fenfluramine. Eur Respir J (1990) 0.91
Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa (1985) 0.91
Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest (1984) 0.90
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 7.08
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med (1995) 6.97
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. N Engl J Med (1997) 5.17
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Inhibition of exercise-induced asthma by a calcium antagonist, nifedipine. Am Rev Respir Dis (1981) 3.00
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med (2000) 2.25
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut (1996) 1.72
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest (1999) 1.70
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol (2001) 1.65
The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev (2009) 1.60
Pancreatic lesions in AIDS. Lancet (1987) 1.55
Thrombotic risk factors in pulmonary hypertension. Eur Respir J (2000) 1.54
Double lung transplantation in situs inversus with Kartagener's syndrome. Paris-Sud University Lung Transplant Group. J Thorac Cardiovasc Surg (1994) 1.53
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J (1998) 1.51
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med (2000) 1.51
Diagnosis and management of subsegmental pulmonary embolism. J Thromb Haemost (2006) 1.47
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med (1995) 1.46
Pulmonary vascular disorders in portal hypertension. Eur Respir J (1998) 1.44
5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol (2000) 1.42
Asymmetric lateral mobility of phospholipids in the human erythrocyte membrane. Proc Natl Acad Sci U S A (1986) 1.41
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax (2004) 1.40
[Lung transplantation]. Presse Med (1989) 1.39
Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. Eur Respir Rev (2009) 1.39
Management of severe pulmonary arterial hypertension. Eur Respir Rev (2010) 1.38
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest (1994) 1.38
Pulmonary veno-occlusive disease. Eur Respir J (2009) 1.37
Pentamidine and pancreatitis. Ann Intern Med (1986) 1.34
Lymphoid interstitial pneumonitis in acquired immunodeficiency syndrome-related complex. Am Rev Respir Dis (1985) 1.32
Long term imatinib treatment in pulmonary arterial hypertension. Thorax (2006) 1.32
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J (2002) 1.31
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax (2005) 1.29
Intraesophageal perfusion of acid increases the bronchomotor response to methacholine and to isocapnic hyperventilation in asthmatic subjects. Am Rev Respir Dis (1986) 1.26
Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation (1994) 1.24
Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med (2001) 1.23
Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med (2000) 1.23
Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med (1981) 1.21
Risk factors for pulmonary arterial hypertension. Clin Chest Med (2001) 1.20
Diaphragm dysfunction induced by upper abdominal surgery. Role of postoperative pain. Am Rev Respir Dis (1983) 1.19
Effects of five different organic calcium antagonists on guinea-pig isolated trachea. Br J Pharmacol (1984) 1.16
Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut (1994) 1.16
Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J (2010) 1.13
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J (2006) 1.11
Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J (2006) 1.11
Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med (2001) 1.11
Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. Eur Respir J (2009) 1.11
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J (2010) 1.10